The FDA has approved a new 7.5 mcg/hour dosage strength of Butrans® (buprenorphine) Transdermal System CIII from Purdue Pharma.

“This approval provides healthcare professionals another option to tailor Butrans therapy to the individual needs of appropriate chronic pain patients,” said Todd Baumgartner, M.D., MPH, Vice President of Research & Development and Chief Medical Officer at Purdue Pharma L.P. “The introduction of the 7.5 mcg/hour dosage strength further demonstrates Purdue’s ongoing commitment to the management of chronic pain.”